The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICLE 2022 | CD1c-restricted T cells as a potential immunotherapy for leukemia
Michela Consonni, PhD, San Raffaele Scientific Institute, Milan, Italy, discusses research relating to the identification of CD1c, a major histocompatibility complex (MHC) class I-like molecule, and its potential as a target against leukemia. CD1c autoreactive T-cells recognize methyl-lysophosphatidic acids (mLPAs), which are expressed on leukemic cells. As CD1c is additionally only expressed in hematopoietic cells, the risk of graft versus host disease (GvHD) is lowered, and lipid-specific T cells may subsequently provide an alternative to chimeric antigen receptor (CAR) T-cell and T-cell receptor (TCR) therapy in patients with acute myeloid leukemia (AML). This interview took place at the International Conference on Lymphocyte Engineering (ICLE) 2022.
